Literature DB >> 21227062

Transdifferentiation of cultured human prostate cancer cells to a neuroendocrine cell phenotype in a hormone-depleted medium.

R Shen1, T Dorai, M Szaboles, A E Katz, C A Olsson, R Buttyan.   

Abstract

Neuroendocrine (NE) cells are enigmatically found in association with human prostate cancers and their numbers are reported to increase in advanced and hormoneresistant tumors. The origin of this cell type and the reason for their appearance in prostate tumors remains unresolved. Previously, Bang et al. (Proc Natl Acad Sci USA 1994;91:5330) reported that dibutyryl adenosine 3',5'-cyclic phosphate (db-cAMP), an agent that upregulates intracellular cAMP, was able to induce a NE cell-like phenotype of cultured human prostate cancer cells, including the androgen-sensitive LNCaP line. Here we report that chronic incubation of LNCaP cells in a medium containing 10% charcoal-stripped fetal bovine serum (CSFBS) likewise induces NE differentiation of these cells. Within 5 days of switching low density cultures of LNCaP cells to this modified medium, the cells growth arrest and acquire an altered morphology with numerous cytoplasmic secretory granules and elongated processes that resemble cultured neurons. This morphology predominates at 10 days with complete transformation seen by 20 days of culture. Electron microscopic analysis of sections of CS-FBS maintained cells showed the presence of abundant dense core secretory granules characteristic of NE cells. Immunohistochemical staining identified the upregulation of the expression of NE markers bombesin, neuron-specific enolase, and S-100 in this modified culture medium. Once established, the NE cell-like phenotype was found to be reversible upon replacement with a medium containing unmodified fetal bovine serum, but not by direct supplementation of CS-FBS medium with dihydrotestosterone (DHT) (I nM). DHT supplementation did, however, suppress the development of the NE cell-like phenotype when it was present at the initiation of exposure to CS-FBS medium. In contrast to db-cAMP treatment, which did not affect prostate specific antigen (PSA) or androgen receptor (AR) expression of LNCaP cells, NE-differentiated LNCaP cells derived in this hormone-deficient medium showed marked downregulation of PSA and AR expression. These in vitro results further support the concept that prostate cancer cells can tranform in vivo to cells with a NE phenotype and suggest that this transformation might be accelerated in patients by certain therapies for prostate cancer.

Entities:  

Year:  1997        PMID: 21227062     DOI: 10.1016/s1078-1439(97)00039-2

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  44 in total

1.  Expression of receptor protein tyrosine phosphatase alpha mRNA in human prostate cancer cell lines.

Authors:  S Zelivianski; J Dean; D Madhavan; F F Lin; M F Lin
Journal:  Mol Cell Biochem       Date:  2000-05       Impact factor: 3.396

2.  Androgen receptor signaling regulates T-type Ca2+ channel expression and neuroendocrine differentiation in prostate cancer cells.

Authors:  Megan Hall; Bryan Todd; Edwin D Allen; Nga Nguyen; Yoon-Jung Kwon; Vu Nguyen; Jennifer L Hearne; Miguel Martin-Caraballo
Journal:  Am J Cancer Res       Date:  2018-04-01       Impact factor: 6.166

3.  Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer.

Authors:  Mark P Labrecque; Ilsa M Coleman; Lisha G Brown; Lawrence D True; Lori Kollath; Bryce Lakely; Holly M Nguyen; Yu C Yang; Rui M Gil da Costa; Arja Kaipainen; Roger Coleman; Celestia S Higano; Evan Y Yu; Heather H Cheng; Elahe A Mostaghel; Bruce Montgomery; Michael T Schweizer; Andrew C Hsieh; Daniel W Lin; Eva Corey; Peter S Nelson; Colm Morrissey
Journal:  J Clin Invest       Date:  2019-07-30       Impact factor: 14.808

Review 4.  Mixed Neuroendocrine-Nonneuroendocrine Neoplasms (MiNENs): Unifying the Concept of a Heterogeneous Group of Neoplasms.

Authors:  Stefano La Rosa; Fausto Sessa; Silvia Uccella
Journal:  Endocr Pathol       Date:  2016-12       Impact factor: 3.943

5.  Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway.

Authors:  A Dirican; H Atmaca; E Bozkurt; C Erten; B Karaca; R Uslu
Journal:  Clin Transl Oncol       Date:  2014-07-25       Impact factor: 3.405

6.  Neuronal Trans-Differentiation in Prostate Cancer Cells.

Authors:  Andrew Farach; Yi Ding; MinJae Lee; Chad Creighton; Nikki A Delk; Michael Ittmann; Brian Miles; David Rowley; Mary C Farach-Carson; Gustavo E Ayala
Journal:  Prostate       Date:  2016-07-12       Impact factor: 4.104

7.  Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells.

Authors:  P D Deeble; D J Murphy; S J Parsons; M E Cox
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

8.  A basal stem cell signature identifies aggressive prostate cancer phenotypes.

Authors:  Bryan A Smith; Artem Sokolov; Vladislav Uzunangelov; Robert Baertsch; Yulia Newton; Kiley Graim; Colleen Mathis; Donghui Cheng; Joshua M Stuart; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2015-10-12       Impact factor: 11.205

9.  EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.

Authors:  Rosa M Martín-Orozco; Carmén Almaraz-Pro; F Javier Rodríguez-Ubreva; M Alicia Cortés; Santiago Ropero; Ramón Colomer; Pilar López-Ruiz; Begoña Colás
Journal:  Neoplasia       Date:  2007-08       Impact factor: 5.715

10.  Sphingosine kinase-1 is central to androgen-regulated prostate cancer growth and survival.

Authors:  Audrey Dayon; Leyre Brizuela; Claire Martin; Catherine Mazerolles; Nelly Pirot; Nicolas Doumerc; Leonor Nogueira; Muriel Golzio; Justin Teissié; Guy Serre; Pascal Rischmann; Bernard Malavaud; Olivier Cuvillier
Journal:  PLoS One       Date:  2009-11-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.